Scheen AJ. Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 Oct; 16(10):556-577.
Scheen AJ, Paquot N. [A revolution in the management of type 2 diabetes : antidiabetic agents providing a cardiovascular and renal protection independently of glucose control !] Rev Med Liege. 2020 May; 75(5-6):392-398. French.
Scheen AJ, Ancion A, Lancellotti P. [Role of SGLT2 inhibitors (gliflozins) in heart failure]. Rev Med Suisse. 2022 Aug 24 ; 18(792):1546-1550. French.
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21; 42(36):3599-3726.
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020 Oct; 98(4S):S1-S115.
Scheen AJ, Delanaye P. Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease. Expert Rev Endocrinol Metab. 2022 Jan; 17(1): 35-46.
Scheen AJ, Paquot N. [Potentiation of weight reduction with GLP-1 receptor agonists]. Rev Med Suisse. 2021 Aug 25; 17(747):1405-1410. French.
Scheen AJ, Radermecker RP, Paquot N. [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes]. Rev Med Suisse. 2022 Aug 24 ; 18(792): 1539-1544. French.
